December 17, 2018 09:54 AM EST

Novo Nordisk grabs a $486M buyout option on an anti-apoC3 antibody for its cardio R&D group

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?